|
FDA Addresses Gender Differences in ICH QT Guidance Revision
The FDA has revised and clarified a final ICH question-and-answer guidance on the evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives